|
Real-time Estimate
Other stock markets
|
5-day change | 1st Jan Change | ||
| 747.50 USD | -0.25% |
|
-1.50% | -3.59% |
Business description: Regeneron Pharmaceuticals, Inc.
- revenues from collaboration agreements (51.1%): collaboration with Sanofi (80.3% of revenues), Bayer (19.4%) and other (0.3%);
- revenues from product sales (30%);
- revenues from sales of technology licenses and subcontracted research services (4.9%).
At the end of 2025, the group had a portfolio of approximately 45 products in clinical development.
Number of employees: 15,410
Sales by Activity: Regeneron Pharmaceuticals, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|---|---|---|---|---|
Discovery, Development, and Commercialization of Medicines for Serious Diseases | 16.07B | 12.17B | 13.12B | 14.2B | 14.34B |
Geographical breakdown of sales: Regeneron Pharmaceuticals, Inc.
| Fiscal Period: December | 2021 (USD) | 2022 (USD) | 2023 (USD) | 2024 (USD) | 2025 (USD) |
|---|
Executive Committee: Regeneron Pharmaceuticals, Inc.
| Manager | Title | Age | Since |
|---|---|---|---|
| President | 66 | 2000-12-31 | |
| Chief Executive Officer | 73 | 1988-01-07 | |
| Director of Finance/CFO | 55 | 2024-02-04 | |
Rajesh Ahuja
COO | Chief Operating Officer | - | 2012-12-31 |
Melissa Lozner
CMP | Compliance Officer | - | 2021-12-31 |
Composition of the Board of Directors: Regeneron Pharmaceuticals, Inc.
| Director | Title | Age | Since |
|---|---|---|---|
| Chairman | 73 | 2023-06-08 | |
Michael Brown
BRD | Director/Board Member | 85 | 1991-05-31 |
Joseph Goldstein
BRD | Director/Board Member | 85 | 1991-05-31 |
George Sing
BRD | Director/Board Member | 76 | 1988-01-07 |
| Chairman | 66 | 2023-06-08 | |
Arthur Ryan
BRD | Director/Board Member | 83 | 2002-12-31 |
Christine Poon
BRD | Director/Board Member | 73 | 2010-11-11 |
Bonnie Bassler
BRD | Director/Board Member | 63 | 2016-09-11 |
Huda Zoghbi
BRD | Director/Board Member | 71 | 2016-09-11 |
N. Coles
BRD | Director/Board Member | 65 | 2017-02-16 |
Holdings: Regeneron Pharmaceuticals, Inc.
| Name | Equities | % | Valuation |
|---|---|---|---|
| 3,702,995 | 3.13% | 47 M $ | |
ADICET BIO, INC. 0.63% | 60,511 | 0.63% | 412 080 $ |
Company details: Regeneron Pharmaceuticals, Inc.
Regeneron Pharmaceuticals, Inc.
777 Old Saw Mill River Road
10591-6707, Tarrytown
+914 847 7000
http://www.regeneron.com
Group companies: Regeneron Pharmaceuticals, Inc.
| Name | Category and Sector |
|---|---|
Regeneron Ireland DAC
 Regeneron Ireland DAC BiotechnologyHealth Technology Operates as a biotechnology company which develops medicines for serious diseases |
Biotechnology
|
Regeneron Ireland DAC
Regeneron Ireland DAC BiotechnologyHealth Technology Operates as a biotechnology company which develops medicines for serious diseases |
Biotechnology
|
Biopharmaceuticals
| Change | 5d. change | 1-year change | 3-years change | Capi.($) | ||
|---|---|---|---|---|---|---|
 | -0.25% | -1.50% | +32.54% | -7.06% | 76.9B | |
| -4.59% | -8.68% | +76.25% | +181.76% | 58.1B | |
| -1.06% | +58.80% | +58.80% | +58.80% | 50.55B | |
| -0.31% | -0.21% | -42.76% | -54.31% | 47.27B | |
| +2.21% | +4.67% | +60.80% | -36.28% | 26.91B | |
| +0.35% | +3.77% | +118.19% | -61.07% | 21.65B | |
| -0.04% | -0.96% | +70.33% | +29.71% | 19.29B | |
| -1.48% | +0.19% | +55.16% | +54.81% | 15.83B | |
| -0.57% | -2.59% | +126.53% | +378.02% | 14.87B | |
| -0.67% | +4.38% | -6.11% | +688.46% | 13.53B | |
| Average | -0.65% | +0.66% | +54.97% | +123.28% | 34.49B | |
| Weighted average by Cap. | -0.96% | -0.14% | +46.70% | +71.02% |
Sector
Trader
This super rating is the result of a weighted average of the rankings based on the following ratings: Valuation (Composite), EPS Revisions (4 months), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Investor
This super composite rating is the result of a weighted average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), EPS Revisions (1 year), and Visibility (Composite). We recommend that you carefully review the associated descriptions.
Global
This composite rating is the result of an average of the rankings based on the following ratings: Fundamentals (Composite), Valuation (Composite), Financial Estimates Revisions (Composite), Consensus (Composite) and Visibility (Composite). The company must be covered by at least 4 of these 5 ratings for the calculation to be carried out. We recommend that you carefully review the associated descriptions.
Quality
This composite rating is the result of an average of rankings based on the following ratings: Returns (Composite), Profitability (Composite) and Quality of Financial Reporting (Composite), and Financial Health (Composite). The company must be covered by at least 2 of these 3 ratings for the calculation to be performed. We recommend that you carefully read the associated descriptions.
ESG MSCI
The MSCI ESG score assesses a company’s environmental, social, and governance practices relative to its industry peers. Companies are rated from CCC (laggard) to AAA (leader). This rating helps investors incorporate sustainability risks and opportunities into their investment decisions.
Quarterly revenue - Rate of surprise
- Stock Market
- Equities
- REGN Stock
- Company Regeneron Pharmaceuticals, Inc.
Select your edition
All financial news and data tailored to specific country editions
